review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1038753656 |
P356 | DOI | 10.1038/NRCARDIO.2009.11 |
P698 | PubMed publication ID | 19352334 |
P2093 | author name string | Peter A McCullough | |
Varun Agrawal | |||
Mohit Agarwal | |||
Victor Marinescu | |||
P2860 | cites work | Statin induced proteinuria: renal injury or renoprotection? | Q80512696 |
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotens | Q80796915 | ||
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group | Q81178841 | ||
Glomerular disease related to anti-VEGF therapy | Q81441190 | ||
Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients | Q81976625 | ||
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
Chronic kidney disease and mortality risk: a systematic review | Q28243131 | ||
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
Role of oxidative modifications in atherosclerosis | Q29617974 | ||
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials | Q30841365 | ||
Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. | Q31046296 | ||
Evidence of transcellular permeability pathway in microvessels | Q31853436 | ||
Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. | Q33959305 | ||
The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus | Q34200394 | ||
Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi | Q34272627 | ||
Leptin and renal disease | Q34482861 | ||
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy | Q34753900 | ||
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation | Q34765654 | ||
Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure | Q35025394 | ||
Proteinuria: how to evaluate an important finding | Q35163370 | ||
Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension | Q35918670 | ||
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria | Q35918674 | ||
Chronic renal failure: a cardiovascular risk factor | Q36335324 | ||
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis | Q36348728 | ||
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). | Q36456306 | ||
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer | Q36509678 | ||
How does proteinuria cause progressive renal damage? | Q36621209 | ||
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. | Q36677348 | ||
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis | Q36721468 | ||
Testing for chronic kidney disease: a position statement from the National Kidney Foundation | Q36894958 | ||
Microalbuminuria and cardiovascular disease | Q36910612 | ||
Incidence and risk factors for stroke in American Indians: the Strong Heart Study | Q37368441 | ||
Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy | Q39437715 | ||
Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort | Q40331970 | ||
Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography | Q40501382 | ||
Transport of macromolecules through microvascular walls | Q41208119 | ||
Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? | Q41270846 | ||
Atherosclerosis and the two faces of endothelial nitric oxide synthase | Q41690339 | ||
Cytoskeletal rearrangement mediates human microvascular endothelial tight junction modulation by cytokines | Q42442374 | ||
Familial aggregation of coronary artery calcium in families with type 2 diabetes | Q43566169 | ||
The prognostic significance of proteinuria: the Framingham study | Q43852381 | ||
Competing risk factor analysis of end-stage renal disease and mortality in chronic kidney disease | Q43888780 | ||
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death | Q43935480 | ||
Effect of pravastatin on proteinuria in patients with well-controlled hypertension | Q44053702 | ||
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. | Q44338046 | ||
Endothelial dysfunction and inflammation in asymptomatic proteinuria. | Q44358537 | ||
Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population | Q44513905 | ||
Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up: the Honolulu Heart Program | Q44970745 | ||
Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients | Q44975136 | ||
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy | Q45012594 | ||
Prevalence of hypertension in renal disease | Q45020640 | ||
A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study | Q45150538 | ||
Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials | Q45897743 | ||
Determinants of coronary artery calcification in diabetics with and without nephropathy. | Q46008035 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people | Q46576858 | ||
Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers | Q46598175 | ||
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. | Q46635485 | ||
Albuminuria and incident coronary heart disease in Australian Aboriginal people | Q46654222 | ||
Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies | Q46822599 | ||
Beneficial impact of spironolactone in diabetic nephropathy | Q46826573 | ||
The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population | Q46963308 | ||
Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients | Q46966140 | ||
Correlates of systolic hypertension in patients with chronic kidney disease | Q48539717 | ||
Screening for proteinuria in US adults: a cost-effectiveness analysis. | Q50735258 | ||
Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. | Q54348402 | ||
Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study | Q57218466 | ||
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy | Q57704237 | ||
Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study | Q57740575 | ||
Proteinuria and interstitial injury | Q57741376 | ||
Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects | Q57791049 | ||
Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication | Q57791545 | ||
EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME | Q57791799 | ||
ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease | Q58949457 | ||
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy | Q60218020 | ||
Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population | Q61965156 | ||
Glomerular and hormonal responses to dietary protein intake in human renal disease | Q69014924 | ||
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group | Q70989850 | ||
Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists | Q71208893 | ||
Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects | Q71739880 | ||
Hemorheology, plasma protein composition and von Willebrand factor in type I diabetic nephropathy | Q71752285 | ||
The increased risk of coronary heart disease associated with nephrotic syndrome | Q72581796 | ||
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria | Q72664928 | ||
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes | Q73321686 | ||
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients | Q73425316 | ||
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) | Q73499190 | ||
The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus | Q73733629 | ||
Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women | Q74256386 | ||
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide | Q74816907 | ||
Hyperlipidemia in patients with chronic renal disease | Q77573739 | ||
Rising tide of cardiovascular disease in American Indians. The Strong Heart Study | Q77726057 | ||
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease | Q79226809 | ||
Proteinuria as a significant determinant of hypertension in a normotensive screened cohort in Okinawa, Japan | Q79649263 | ||
Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study | Q79702558 | ||
Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization | Q79811373 | ||
Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population--the Ohasama study | Q80065099 | ||
Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening | Q80087723 | ||
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency | Q80313261 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | circulatory system | Q11068 |
P304 | page(s) | 301-311 | |
P577 | publication date | 2009-04-01 | |
P1433 | published in | Nature Reviews Cardiology | Q2108444 |
P1476 | title | Cardiovascular implications of proteinuria: an indicator of chronic kidney disease | |
P478 | volume | 6 |
Q37582474 | A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults |
Q37340221 | A randomized trial of dietary sodium restriction in CKD |
Q50217744 | A red-NIR emissive probe for the selective detection of albumin in urine samples and live cells |
Q37936466 | A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients |
Q33615038 | Ameliorating Adriamycin-Induced Chronic Kidney Disease in Rats by Orally Administrated Cardiotoxin from Naja naja atra Venom |
Q55395967 | Any grade of relative overhydration is associated with long-term mortality in patients with Stages 4 and 5 non-dialysis chronic kidney disease. |
Q37280823 | Association of cholesterol levels with mortality and cardiovascular events among patients with CKD and different amounts of proteinuria |
Q52381520 | Association of renal hyperfiltration with incident proteinuria - A nationwide registry study. |
Q37943290 | Balancing calcium signals through TRPC5 and TRPC6 in podocytes |
Q34373061 | Cardiorenal syndromes: pathophysiology to prevention |
Q33746507 | Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). |
Q101038925 | Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis |
Q37557361 | Cardiovascular risk factors in patients with chronic kidney disease |
Q47112805 | Cardiovascular risks in chronic kidney disease pediatric patients |
Q90259050 | Causes of late transplant failure in cyclosporine-treated kidney allograft recipients |
Q90264301 | Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets |
Q39512534 | Chronic kidney disease and risk of mortality, cardiovascular events or end-stage renal disease in older patients with hypertension. |
Q33870791 | Decreased Estimated Glomerular Filtration Rate (eGFR), Not Proteinuria, Is Associated with Asymptomatic Intracranial Arterial Stenosis in Chinese General Population. |
Q35931836 | Dendrin ablation prolongs life span by delaying kidney failure. |
Q47108714 | Determination of the optimal target level of proteinuria in the management of patients with glomerular diseases by using different definitions of proteinuria |
Q33725864 | Effect of Kidney Dysfunction on Cerebral Cortical Thinning in Elderly Population. |
Q46169904 | Effects of gum arabic (Acacia senegal) on renal function in diabetic mice |
Q35995060 | Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease |
Q92822880 | Extracellular Vesicles from Albumin-Induced Tubular Epithelial Cells Promote the M1 Macrophage Phenotype by Targeting Klotho |
Q49588056 | Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3. |
Q89726296 | Intravenous administration of iPS-MSCSPIONs mobilized into CKD parenchyma and effectively preserved residual renal function in CKD rat |
Q87499215 | Is neutrophil lymphocyte ratio an indicator for proteinuria in chronic kidney disease? |
Q53318467 | Multidetector computed tomography findings and correlations with proteinuria in nutcracker syndrome. |
Q35841718 | New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil |
Q37219039 | Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease |
Q43243041 | Prenatal exposure to lipopolysaccharide alters the intrarenal renin-angiotensin system and renal damage in offspring rats |
Q91578856 | Preoperative proteinuria is associated with increased rates of acute kidney injury after partial nephrectomy |
Q41108699 | Proteinuria Detected by Urine Dipstick Test as a Risk Factor for Atrial Fibrillation: A Nationwide Population-Based Study |
Q37414937 | Proteinuria and its relation to cardiovascular disease |
Q38057664 | Proteinuria and progression of glomerular diseases |
Q35053592 | Proteinuria independently predicts unfavorable outcome of ischemic stroke patients receiving intravenous thrombolysis |
Q33890104 | SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial |
Q38513740 | Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? |
Q47779331 | The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). |
Q34452637 | The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. |
Q33583220 | The effects of glucose-lowering therapies on diabetic kidney disease |